News

Filter

1 to 9 of 17 results

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

06-02-2014

‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal…

AstraZenecaBrilintaCardio-vascularCrestorDiabetesExenatide InjectionFinancialInterviewsNexiumOncologyPharmaceuticalRespiratory and PulmonarySymbicortUK

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Akrikhin expands deal with Merck & Co

08-08-2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline

02-08-2013

German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Japanese approvals for Eylea, Tresiba, Seebri and Aimix

01-10-2012

There was a flurry of announcements from Japan's Ministry of Health, Labor and Welfare (MHLW) on Friday,…

AimixAsia-PacificBayerCardio-vascularDainippon Sumitomo PharmaDiabetesEyleaNovartisNovo NordiskOphthalmicsPharmaceuticalRegeneronRegulationRespiratory and PulmonarySeebri BreezhalerShionogiTresibaVectura

Targacept to drop TC-6987 in diabetes on mixed trial results

28-03-2012

US drug developer Targacept (Nasdaq: TRGT) saw its shares drop 5% to $5.12 ,after the company announced…

DiabetesPharmaceuticalResearchRespiratory and PulmonaryTargacept

1 to 9 of 17 results

Back to top